Jasper Therapeutics, Inc.

The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Current securities

1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 28, 2026
2. 25-NSE - filed by Nasdaq Stock Market LLC regarding Jasper Therapeutics, Inc.Sep 24, 2026
3. Entry into a Material Definitive AgreementAug 26, 2026
4. PRE 14A filingAug 24, 2026
5. SCHEDULE 13G filingAug 17, 2026